CD44 and non-small cell lung carcinoma: The use of an AMPK inhibitor (100 nM of AMPK‐IN‐3) resulted in reduced cell proliferation and EDU cells, inhibited cell metastasis, and increased caspase‐3/9 activity levels in NSCLC with upregulated TRIM11 gene expression (as shown in Figure 5A–E).